Defence Therapeutics Inc Class A · CSE:DTC
Defence Therapeutics Inc Class A — Investor Presentation (June 2024)
32 slides from Defence Therapeutics Inc Class A's investor presentation, June 2024
Slide 1: Investor Presentation
Investor Presentation Biopharmaceutical Innovations for Future Generations CSE: DTC | FSE: DTC | OTCQB: DTCFF Q2 2024
Slide 2: Forward Looking Statements
Investor Presentation | Defence Theurapeutics Forward Looking Statements DEFENCE THERAPEUTICS This presentation contains “forward-looking information” within the meaning Defence’s short operating history; the possibility that Defence may never receive of applicable securities laws in Canada, includi
Slide 3: The Highlights
Investor Presentation | Defence Therapeutics THE HIGHLIGHTS Defence Therapeutics ● Publicly traded biotech firm based in Montreal, Quebec, with an attractive capital structure and loyal investors. ● Patented, highly versatile, proprietary Accum® platform technology, which vastly improves any type of
Slide 4: Our Mandate
Our Mandate To overcome encountered intracellular barriers for almost any treatment directly applicable to: ● Protein/RNA/DNA vaccines ● Antibody-Drug Conjugates ● Any type of biomedicine 4
Slide 5: Problem Driven Solutions for Ineffective Treatments
5 Ineffective Treatments ● Radiation + chemotherapy can kill tumor cells but also healthy cells. ● Nuclear-targeted biopharmaceuticals struggle with molecular obstacles which has limited their possibility to become a therapeutic Problem standard for human diseases (i.e. cancer). Driven Next-Level In
Slide 6: Platform Technology
eGFP-hGal3-Expressing DCs 10 µm Platform Technology antigen-x Accum antigen-x (Damaged endosomes triggered by Accum®) ACCUM® Technology is a proprietary and US patented platform technology, with proven enhanced We have tackled an industry-wide ADC challenge intracellular drug delivery. of Nuclear Lo
Slide 7: How We Do it
Investor Presentation | Defence Theurapeutics How We Do it ACCUM® promotes endosome-to-cytosol escape, by breaking down endosomal membranes. It can therefore be used in the context of: ● Protein or cell-based vaccines ● mRNA or DNA ● ADCs ● New entities with novel pharmacological properties 7
Slide 8: Technology: Turning ADC challenges into proven platform solutions
Investor Presentation | Defence Theurapeutics Technology Turning ADC challenges into proven platform solutions Potential Significance of Accum®Technology ACCUM Talk-Worthy Results ACCUM® Innovative Approach CURRENT POOR Accum® EFFICIENT ACCUMULATION ACCUMULATION Overcoming problematic cell recycling
Slide 9: Defence Therapeutics: Innovative Platform
Investor Presentation | Defence Theurapeutics Defence Therapeutics: Innovative Platform Accum® Molecule BILE ACID NLS Highly Versatile Technology Ideal for the development of Easily applicable to mRNA-DNA- Molecules with anti- Augments the anti-tumoral novel cell-based vaccines , or protein-based va
Slide 10: Global Biopharma Market
Investor Presentation | Defence Theurapeutics 13.8% CAGR from 2018 to 2025 vs. Global Market 3-6% for the global pharmaceuticals $526 Billion Pioneers This indicates GLOBAL BIOPHARMA At 17% of the global biopharmaceuticals are pharmaceutical market, destined to dominate the biopharma is projected to
Slide 11: Valuable Traction: Product Pipeline
Investor Presentation | Defence Theurapeutics PHASE 1- DISCOVERY PRE-CLINICAL CMC IND Filling Valuable 2024 PRODUCT INDICATION RESEARCH & NON-GLP GLP DEVELOPMENT Project Cell Vaccine Traction ARM-X Solid Tumors AccuTOX (Small molecule) AccuTOX-001 Melanoma AccuTOX-IN001 Lung Cancer Protein Vaccine W
Slide 12: Innovating Pathways to Success
Innovating Pathways First to develop a combined Proprietary and versatile Problem-driven solutions Exponential scaling potential, with fully owned assets to be capitalized to Success breakthrough, with technology targeting confirming strong market precision and efficient cell immuno-oncology (IO) po
Slide 13: Cancer Therapeutics
01 Cancer Therapeutics We are leveraging our Accum technology, to create novel immuno-oncology treatments. Through our ADC and AccuTOX, we have been specifically targeting Melanoma, Breast and Lung Cancers within Discovery and Preclinical work and have ADCs with improved bioaccumulation properties t
Slide 14: The AccuTOX Program
14 01 CANCER THERAPEUTICS The AccuTOX Program: Ready for Phase I in The USA and in process for Canada Indication: Melanoma 14
Slide 15: AccuTOX: An Accum Variant with Enhanced Killing Potency
Investor Presentation | Defence Theurapeutics AccuTOX®: An Accum® Variant with Enhanced killing Potency (~30 Fold Increase) (Q4 of 2024) ORIGINAL ACCUM AccuTOX-001 93% 100% 81% 100% 38% 100% 84% 100% 15
Slide 16: AccuTOX-001 Halts Tumor Development With Checkpoint Inhibitors
Investor Presentation | Defence Theurapeutics AccuTOX-001 Halts Tumor Development When Combined with Immune-Checkpoint Inhibitors Synergistic effect against ICI- resistant Tumors 16
Slide 17: AccuTOX-001 Phase Trial: 3+3 Design
Investor Presentation | Defence Theurapeutics AccuTOX-001 Phase 1 Trial: 3+3 Design (Phase I trial cleared by the FDA and in process for Canada) Phase I/II A Phase II AccuTOX-001 + aPD-1 AccuTOX-001 + aPD-1/aLAG-3 Dose Escalation 3+3 Design Dose I AccuTOX-001 Dose II Selected Dose AccuTOX-001 AccuTO
Slide 18: AccuTOX/Anti-PD1 Intranasal Administration
Investor Presentation | Defence Theurapeutics AccuTOX/Anti-PD1 Intranasal Administration Greatly Reduces Lung Nodule Numbers PBS PD-1 AccuTOX AccuTOX PD-1 18
Slide 19: Vaccine Development
02 Vaccine State of the Art Facilities Development Laboratory space of 140 m2, accommodating 12 highly qualified personnel and a wide range of equipment. Access in process to 12 high tech platforms Accelerated Vaccine Development: located at the Institute for Research in Cancer & Infectious Diseases
Slide 20: Cancer Vaccines
Investor Presentation | Defence Theurapeutics 02 Cancer Vaccines We are leveraging our Accum® technology, to create novel immuno-oncology treatments. While studying AccuTOX®, the molecule was shown to elicit specific reprogramming event in mesenchymal stromal cells (MSCs). Therefore, it is used by D
Slide 21: Defence Arm-X Cancer Vaccine
21 02 CANCER VACCINES Defence Arm-X Cancer Vaccine The solution to cure any solid cancer tumors 21
Slide 22: The AccuTOX-Reprogrammed MSC (ARM-X) Cancer Vaccine
Investor Presentation | Defence Theurapeutics The AccuTOX®-Reprogrammed MSC (ARM-X) Cancer Vaccine Patient admission and tumor resection Cell Processing Center Patient Treatment AccuTOX®/ANTIGEN REPROGRAMMING Immune-suppressive MSCs ARM-X 22 Time required to generate the ARM-X vaccine: 24 h
Slide 23: ARM-X Pancreatic Cancer and B16 Melanoma Results
Investor Presentation | Defence Theurapeutics Pancreatic Cancer B16 Melanoma Ctl ARM-X PD-1 ARM-X + PD-1 1600 1000 PBS Tumor volume (mm3) Tumor Volume (mm3) Ctl PD-1 800 PD-1 1200 ARM-X ARM-X 600 ARM-X + PD-1 ARM-X + PD-1 800 MSC 400 400 MSC + PD-1 200 0 0 0 8 16 24 32 40 0 8 16 24 32 40 Timeline (D
Slide 24: ARM-X Phase I Trial in Canada & USA
Investor Presentation | Defence Theurapeutics ARM-X Phase I Trial in Canada & USA (Q1–Q2 of 2025) Part A Part B ARM-X Monotherapy ARM-X + ePD-1 Dose Escalation (3+3 Design) Dose I Dose II Selected Dose Dose III 24
Slide 25: The Protein Vaccine Program
25 02 CANCER VACCINES The Protein Vaccine Program Accum-E7: Cervical Cancer and Head & Neck Tumors 25
Slide 26: Advanced Protein-based Vaccines
Investor Presentation | Defence Theurapeutics Assessment of tumor volume in animals with pre-establsihed cervical cancer treated with Accum-E7 Advanced Protein-based Vaccines Benefiting from the multiplier ability of Accum® (100x), Defence Therapeutics can easily direct the science from one antigen
Slide 27: Corporate & Finance
27 Corporate & Finance 27
Slide 28: Board Members, Advisors and Management
Investor Presentation | Defence Theurapeutics Board Members, Advisors and Management Sebastien Plouffe Kwin Grauer Chief Executive Officer, President & Director Director Financial expert and entrepreneur with 25+ years CA with more than 20 years of experience in experience with public companies, stro
Slide 29: Potential Exits & Liquidity
Investor Presentation | Defence Theurapeutics Potential Exits & Liquidity 2024 2025 2026 2027 2028 2029 2030 AccuTOX® as an injectable (Melanoma) ● Phase I Trial: 2024 – 2026 ● Possible Deal (exit) ● Phase II Trial: 2026 – 2028 ● Partnership for Phase III trial or ARM-X Vaccine (Pancreatic Cancer) B
Slide 30: Capitalization
Investor Presentation | Defence Theurapeutics Capitalization CURRENT ISSUED AND OUTSTANDING 45,436,673 SHARE PURCHASE WARRANTS SHARE PURCHASE WARRANTS - FINDERS Expiry Date Exercise Price Outstanding Expiry Date Exercise Price Outstanding 16-Nov-25 $ 1.75 1,497,780 23-Sep-24 $ 2.50 44,475 30-Jan-26
Slide 31: What Differentiates Defence Therapeutics?
Investor Presentation | Defence Therapeutics What Differentiates Defence Therapeutics? Accum Platform BILE ACID NLS Infinite number Possibility to generate Discovery of new of products hundreds of variants pharmacological properties Versatility 31
Slide 32: Connect
Connect (514) 947 - 2272 info@defencetherapeutics.com www.defencetherapeutics.com 1615 - 200 Burrard Street, Vancouver, BC, V6C 3L6 Laboratories: 7171 Frederick Banting Montreal, QC, H4S 1Z9
Defence Therapeutics — Investor Presentation (June 2024) on 6ix